Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG demonstrates a positive outlook due to promising clinical results from its candidates OCS-01 and OCS-05, particularly with OCS-05 showing potential for significant market share in the treatment of acute optic neuritis and related neuro-ophthalmic conditions. The data indicating meaningful visual acuity gains, such as a +7.6 letter improvement and a 27.4% response rate for ≥15-letter gain, support the clinical efficacy of its products and suggest a strong foundation for future growth. Moreover, the enthusiasm from key opinion leaders and the company's strategic advancement into registrational and exploratory trials highlight its commitment to innovation and potential success in the biopharmaceutical market.

Bears say

Oculis Holding's stock faces a negative outlook primarily due to significant delays in clinical development and regulatory approvals, which could extend timelines and increase costs. Additionally, the lack of data catalysts until the second quarter of 2026 raises concerns about investor engagement and market interest. The company also faces heightened competition from both existing and emerging therapies, which poses a risk to market penetration and pricing strategies for its treatments targeting diabetic macular edema and other eye conditions.

OCS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 5 analysts, OCS has a Strong Buy consensus rating as of Nov 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.